Ambitious Upgrade Program Launched By The ESRF
Main Category: Radiology / Nuclear MedicineAlso Included In: Biology / Biochemistry; IT / Internet / E-mail
Article Date: 30 Nov 2008 - 1:00 PDT
|
|
| Patient / Public: | ![]() |
5 (2 votes) |
| Healthcare Prof: | ![]() |
More than ten thousand scientists across Europe will profit from new investments in the European Synchrotron Radiation Facility (ESRF) approved today. Over the next seven years, unique new experimental facilities for research with X-rays will come into operation. This decision, taken by the ESRF Council, representing the 19 countries financing the ESRF, confirms Europe's vision to expand its global leadership in photon science.
On 24-25 November 2008, the 50th Council meeting of the ESRF approved a 10% budget increase for 2009, to start a 177 million Euros Upgrade Programme over the next seven years (2009-2015). The main element of this programme is the development of new world-class experimental stations (beamlines) which will gradually enter into service as of 2011.
The ESRF Upgrade Programme builds on the fact that no other research infrastructure is growing faster than light sources: since 1994 when the ESRF was inaugurated, more than twenty new synchrotrons opened in Europe, the US and Asia. They produce cutting-edge science, illustrated by the publication of at least one paper on average in every single issue of Science and Naturein 2007. As much as 20% of this global scientific output originated at the ESRF and much of it is relevant to everyday life. Whether it relates to promising targets for a new drug, candidate materials for hydrogen storage in cars, dust grains collected in outer space or liquid-crystal photovoltaic cells, there is a high probability that such research includes experiments at the ESRF to determine structures and properties at the atomic scale with unequalled resolution and accuracy.
"I am convinced that the Upgrade Programme will ensure the competitiveness of the ESRF for the benefit of Europe and European science" says Professor Robert Feidenhans'l, Deputy Director of the Niels-Bohr Institute in Copenhagen and Chairman of the ESRF Council. The five key targets of the Upgrade Programme are:
-
Nanoscience and technology: Molecular machines, quantum dots or self-assembling 2-D crystals sound like magic words today but nanotechnology will be in tomorrow's consumer products. The future nanoscience beamlines at the ESRF are a foundation stone for such nano-engineering.
-
Structural biology and soft matter: Progress in health and life sciences is linked to understanding processes at the atomic scale. There is an explosion today in demand to resolve the structure of molecules for the development of new drugs. A new generation of automated experiments will screen about a thousand samples in a single day.
-
Ultrafast molecular processes: Studying a chemical reaction as it happens, like in a film, is possible today, but not at sufficient speed. Pushing the time-resolution into the picosecond (one trillionth of a second) regime will open new insight in chemical processing, catalysis and how proteins function in living cells.
-
Science at extreme conditions: Developing advanced materials, chemical processing and planetary science all need to put samples under extreme pressure, temperatures and magnetic fields. Whatever the extreme, the ESRF will strive to make it available in situ on one of its beamlines.
- X-ray imaging: Revealing both the 3-D structure and the chemical composition of an object without altering it has countless applications in materials science, cultural heritage and engineering. The objective in this field is to resolve structures smaller than one micrometre.
###
Source: Montserrat Capellas
European Synchrotron Radiation Facility
Visit our radiology / nuclear medicine section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/131164.php>
APA
http://www.medicalnewstoday.com/releases/131164.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




